T1	Participants 96 143	patients with advanced-stage Hodgkin's lymphoma
T2	Participants 731 845	The randomized, three-arm trial recruited patients in stages IIB and IIIA with risk factors and stages IIIB and IV
T3	Participants 1319 1378	505 assessable patients and a median follow-up of 23 months
